Pharmaceuticals and Medical Devices Agency (PMDA)

The Pharmaceuticals and Medical Devices Agency (PMDA) is Japan’s national regulatory authority responsible for ensuring the safety, effectiveness, and quality of pharmaceutical products, medical devices, and advanced healthcare technologies. Established in 2004 and headquartered in Tokyo, Japan, PMDA operates under the supervision of Japan’s Ministry of Health, Labour and Welfare (MHLW).

PMDA performs scientific evaluations of medicines, vaccines, biologics, medical devices, and regenerative medicine products before they receive approval for use in Japan. The agency also conducts post-market safety monitoring and provides regulatory consultations to pharmaceutical and biotechnology companies.

Its major responsibilities include product approval reviews, clinical trial consultations, Good Manufacturing Practice (GMP) inspections, pharmacovigilance activities, medical device assessments, and regulatory science research.

PMDA supports innovation in healthcare by providing guidance for emerging technologies such as cell therapies, gene therapies, regenerative medicine products, and digital healthcare solutions. The agency works closely with researchers, universities, healthcare organizations, and industry partners to promote safe development of advanced medical products.

The organization collaborates internationally with regulatory authorities including the U.S. FDA, European Medicines Agency (EMA), and other global healthcare regulators. PMDA actively participates in international harmonization initiatives such as the International Council for Harmonisation (ICH).

Through scientific evaluation, safety monitoring, and regulatory support, PMDA helps ensure Japanese patients have access to safe and effective medicines and medical technologies while supporting innovation in the global healthcare industry.